Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent medical problem that affects approximately a third of the US population. Patatin-like phospholipase domain containing 3 (PNPLA3) was first implicated in the metabolism of hepatic triacylglycerides (TAGs) when our lab found that a missense mutation that substitutes isoleucine at position 148 with methionine (I148M) was associated with non-alcoholic fatty liver disease in humans. Homozygotes with the variant allele (148M) have a 2-fold higher risk of hepatic TAG accumulation than homozygotes with the wild type allele (148I). The function of PNPLA3 and the cause of I148M induced hepatic TAG accumulation remains unclear. Since fatty liver represents an accumulation of fatty acids in the form of triglycerides, I will adapt and/or develop targeted liquid chromatography-tandem mass spectrometry (LC-MS-MS) methods to measure the concentrations of different classes of fatty acid-containing lipids in liver adipose tissue, and plasma from mouse models of PNPLA3-associated steatosis. Mice will be studied on both a normal chow diet and on diets designed to exacerbate or alleviate PNPLA3-I148M associated accumulation of hepatic TAG. I will then extend these LC-MS/MS-based methods to determine the flux of each lipid class by measuring the rate of incorporation of deuterium from deuterated water (D2O) in cultured cells that overexpress PNPLA3, and in genetically manipulated mouse models. Alternative stable isotope labeling strategies, such as 13C-glycerol or 13C-fatty acid incorporation, will also be employed to compliment the D2O incorporation data. Execution of this research proposal will provide training in the application of metabolomics technology to study human disease and shed insight into the function of PNPLA3 and its role in the progression of fatty liver disease.
Fatty liver disease is a growing epidemic that afflicts a third of the US population and leads to steatosis, cirrhosis, and liver failure. We have identified a gene named PNPLA3 that is strongly associated with fatty liver disease in human, but the function of this gene remains unclear. I am proposing experiments designed to determine the function of PNPLA3 and ultimately aid in the development of effective medical therapies to prevent fatty liver disease.
|Mitsche, Matthew A; Hobbs, Helen H; Cohen, Jonathan C (2018) Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem 293:6958-6968|
|Zhang, Yue; Udayakumar, Durga; Cai, Ling et al. (2017) Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI. JCI Insight 2:|
|Padanad, Mahesh S; Konstantinidou, Georgia; Venkateswaran, Niranjan et al. (2016) Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. Cell Rep 16:1614-1628|
|Aboudehen, Karam; Kim, Min Soo; Mitsche, Matthew et al. (2016) Transcription Factor Hepatocyte Nuclear Factor-1? Regulates Renal Cholesterol Metabolism. J Am Soc Nephrol 27:2408-21|
|Gao, Lu; Rabbitt, Elizabeth H; Condon, Jennifer C et al. (2015) Steroid receptor coactivators 1 and 2 mediate fetal-to-maternal signaling that initiates parturition. J Clin Invest 125:2808-24|
|Mitsche, Matthew A; McDonald, Jeffrey G; Hobbs, Helen H et al. (2015) Flux analysis of cholesterol biosynthesis in vivo reveals multiple tissue and cell-type specific pathways. Elife 4:e07999|
|Wang, Jin; Mitsche, Matthew A; Lütjohann, Dieter et al. (2015) Relative roles of ABCG5/ABCG8 in liver and intestine. J Lipid Res 56:319-30|
|Yang, Chendong; Ko, Bookyung; Hensley, Christopher T et al. (2014) Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell 56:414-24|
|Moon, Young-Ah; Ochoa, Courtney R; Mitsche, Matthew A et al. (2014) Deletion of ELOVL6 blocks the synthesis of oleic acid but does not prevent the development of fatty liver or insulin resistance. J Lipid Res 55:2597-605|